Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This study sets out to determine the maximum tolerated dose (MTD) of afatinib in combination
with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
The identified MTD will serve as recommended phase II dose (RP2D).
Phase:
Phase 1
Details
Lead Sponsor:
PD Dr. med. Volker Heinemann
Collaborators:
Technische Universität München University of Cologne